Free shipping on all orders over $ 500

Utomilumab

Cat. No. M24659
Utomilumab Structure
Synonym:

PF 05082566

Size Price Availability Quantity
Free Delivery on orders over USD 500 Bulk Inquiry?
Quality Control & Documentation
Biological Activity

Utomilumab (PF 05082566) is a fully human IgG2 mAb agonist of the T-cell costimulatory receptor 4-1BB/CD137. Utomilumab can be used for the research of relapsed/refractory follicular lymphoma (FL) and other CD20+ non-Hodgkin lymphomas (NHL).

Chemical Information
Molecular Weight 388.42
Formula C17H24N8O3
CAS Number 1417318-27-4
Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Omid Hamid, et al. J Immunother Cancer. First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors

[2] David S Hong, et al. Front Immunol. Utomilumab in Patients With Immune Checkpoint Inhibitor-Refractory Melanoma and Non-Small-Cell Lung Cancer

[3] Kenji Hashimoto. Cancers (Basel). CD137 as an Attractive T Cell Co-Stimulatory Target in the TNFRSF for Immuno-Oncology Drυg Development

[4] Ajay K Gopal, et al. Clin Cancer Res. First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas

[5] Cariad Chester, et al. Blood. Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies

Related TNF Receptor Products
FS120

FS120 is a first-in-class dual-agonist tetravalent bispecific antibody targeting CD137 (4-1BB, TNFRSF9) and OX40 (CD134, TNFRSF4). FS120 has the potential to show activity in "cold" tumors and improve outcomes of existing immunotherapies by simultaneously agonizing CD137 and OX40.
ATOR-1015

ATOR-1015 is a human CTLA-4 x OX40 targeting IgG1 bispecific antibody with enhanced immune activation and tumor-directed activity for improved efficacy and reduced toxicity. ATOR-1015 induces T-cell activation and Treg depletion in vitro.
YH002

YH002 is a recombinant anti-OX40 (CD134, TNFRSF4) humanized IgG1 agonistic antibody.
HFB 3010

HFB 3010 (HFB 301001) is a novel second-generation fully human IgG1 class OX40 agonistic monoclonal antibody.
MEDI6469

MEDI6469 is an activating monoclonal antibody to TNFRSF4 (OX40, CD134), which mimics the binding of the ligand, TNFSF4 (OX40L, CD252), to stimulate proliferation of T-cells and enhance an anti-tumor response.
  Catalog
Abmole Inhibitor Catalog




Keywords: Utomilumab, PF 05082566 supplier, TNF Receptor, inhibitors, activators

 
Get to Know Us
Customer Support
Resources
Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.